ALA's Principal Activity is the pharmaceutical development and to acquire new platforms that align with oncology and conditions that affect the central nervous system.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-12.30%|
|ASX Rank||1,869 of 2,399|
|Sector Rank||171 of 207|
Arovella Therapeutics Limited (ALA, formerly Suda Pharmaceuticals Ltd)is a biotechnology company focused on developing therapies to treat human disease. Arovella's two focus areas are oncology and conditions that impact the central nervous system. Arovella is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers.
Incorporated in Perth on 21/12/1999.
DPS and Yield calculations use the Pay Date.
|Dr Elizabeth Stoner||Non-Executive Director||Nov 2021||
Dr Elizabeth Stoner
Dr Stoner has over 30 years of experience in the life-sciences sector, spanning earlystage research, drug development and venture investing. She is currently Executive Partner at MPM Capital, with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. In her role, Dr Stoner serves as a clinical advisor to several of MPM Capital's portfolio companies, including AlloVir, and Rhythm Pharmaceuticals. Additionally, Dr Stoner served as the interim CEO of the cell therapy biotechnology company, Semma Therapeutics, which was acquired by Vertex in 2019 for US$950 million. Prior to joining MPM Capital, Dr Stoner was Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries. While at Merck, she also oversaw the clinical development activities of its Japanese subsidiary. Previously, she led the 5- alpha reductase clinical development program. Dr Stoner currently serves on the board of Triplett Therapeutics. She is also a member of the Albert Einstein College of Medicine Board of Governors, and the Weill Cornell Medical College Clinical and Translational Science Center External Advisory Board. Prior to joining the biopharma industry, she was an Assistant Professor of Paediatrics at Cornell University Medical College.
|Dr Debora Barton||Non-Executive Director||Aug 2021||
Dr Debora Barton
Dr Barton has over 20 years' experience in the field of oncology. After practicing oncology as a physician and clinical trial investigator, she spent five years at Novartis and five years at Celgene in roles of increasing responsibilities in Medical Affairs and Clinical Development. Dr Barton has experience working with cell therapy products, formerly as the Senior Vice President, Clinical and Head of Safety, of the clinical stage company, Iovance, who are developing T cell therapies for cancer treatment. Dr Barton is currently the Chief Medical Officer of Carisma Therapeutics, a clinical stage biopharmaceutical company, developing innovative immunotherapies including the first in class chimeric antigen receptor (CAR) macrophages for the treatment of certain cancers. Dr Barton is a member of the Manhattan Board of Directors for the American Cancer Society and is also a member of the Medical Advisory Board of the Tigerlily Foundation, a national breast cancer foundation providing education, awareness, advocacy and hands-on support to young women before, during and after breast cancer.
|Mr Phillip Hains||Company Secretary||Jul 2020|
|Dr Michael Baker||Chief Executive Officer,Managing Director||Jan 2020||
Dr Michael Baker
Chief Executive Officer,Managing Director
Dr Baker has over 15 years of experience in scientific research, drug development and venture investing. He was an Investment Manager with leading Australian life science fund, BioScience Managers, responsible for deal sourcing from networks, conferences, universities and research institutes. He also conducted due diligence to shortlist investment opportunities and played a role in managing portfolio companies. He is Member of Risk Committee and HR Committee.
|Mr Paul Alex Hopper||Non-Executive Chairman,Non-Executive Director||Sep 2019||
Mr Paul Alex Hopper
Non-Executive Chairman,Non-Executive Director
Mr Hopper has over 20 years' experience in the management and funding of biotechnology and healthcare public companies both as Chief Executive Officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas with focus on immunotherapy and cancer vaccines. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. He is Director of Radiopharm Theranostics Limited, since 11 February 2021, Chimeric Therapeutics Limited (ASX: CHM), since 2 February 2020, Imugene Limited, since 31 October 2012, Scopus BioPharma Inc (New York) (Stat3 technology), since December 2020. He is Chair of the HR Committee and Member of Risk Committee.
|Mr David Simmonds||Non-Executive Director||Mar 2019||
Mr David Simmonds
Mr Simmonds was a senior audit partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. As an audit partner, David was involved in several businesses including Ramsay Health Care Ltd, John Fairfax Holdings and Commonwealth Bank of Australia and also was audit partner for the Australian operations of the leading US technology companies Hewlett Packard, Sun Microsystems and Oracle. David was a member of the Board and chaired the Audit, Risk and Finance Committee of MS Research Australia. He is Chair of Risk Committee and Member of HR Committee.
ALA directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|16/12/21||Elizabeth Stoner||Issued||2,400,000||$0.04||$96,000||Issue of options|
|16/12/21||Debora Barton||Issued||2,400,000||$0.04||$96,000||Issue of options|
|16/12/21||Paul Hopper||Issued||6,000,000||$0.04||$240,000||Issue of options|
|15/12/21||Michael Baker||Buy||+650,000||$0.039||$25,350||On-market trade|
|15/12/21||Paul Hopper||Buy||+1,000,000||$0.04||$40,000||On-market trade|
|11/11/21||Michael Baker||Issued||8,000,000||$0.041||$328,000||Issued under employee share plan|
The current holdings of ALA directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
No Substantial Shareholders for ALA in our database.
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.